Effect of sarpogrelate treatment on 5-HT modulation of vascular sympathetic innervation and platelet activity in diabetic rats

• Published in: Biomedicine & pharmacotherapy 2022-09, Vol.153, p.113276-113276, Article 113276
• Main Authors: Fernández-González, Juan Francisco, García-Pedraza, José Ángel, Marín-Quílez, Ana, Bastida, José María, Martín, María Luisa, Morán, Asunción, García-Domingo, Mónica
• Format: Article
• Language: English
• Subjects: 5-HT; 5-HT1D/7 receptors; 5-HT2 antagonism; Diabetes; Platelet activation; Sympathetic neurotransmission
• ISSN: 0753-3322; 1950-6007
• DOI: 10.1016/j.biopha.2022.113276

This study aimed to investigate whether the 5-HT2 receptor blockade alters the 5-HT effect on vascular sympathetic neurotransmission and platelet activation in type 1 diabetes. 28-day diabetes was obtained by alloxan (150 mg/kg; s.c.) in male Wistar rats, administering sarpogrelate (5-HT2 blocker; 30 mg/kg/day; p.o.) for 14 days. Blood glucose and body weight were monitored for 28 days. After 4 weeks of diabetes induction, food and drink intake, urine, plasma-platelet 5-HT, and platelet activation were determined in normoglycemic, non-treated diabetic and sarpogrelate-treated diabetic rats. Another set of diabetic rats were pithed to run the vascular sympathetic stimulation or exogenous noradrenaline administration, examining the induced vasoconstrictor responses. Sarpogrelate treatment significantly reduced drink intake and urine, whereas BW gain, hyperglycemia, and food intake were not modified in diabetic rats. The platelet activation and plasma 5-HT concentration were decreased (increasing the stored 5-HT platelet) by 5-HT2 blockade in diabetic animals. The sympathetic-induced vasoconstrictions were higher in non-treated than in sarpogrelate-treated diabetic rats. 5-HT inhibited these vasopressor responses, reproduced exclusively by the 5-HT1/5/7 receptor agonist, 5-CT. The 5-CT-produced inhibition was partly reversed by 5-HT1D or 5-HT7 antagonists (LY310762 or SB-258719, respectively), and totally annulled by the mixture of LY310762+SB‐258719. Noradrenaline-caused vasoconstrictions were also decreased by 5-CT. In conclusion, our results reveal that 14-day sarpogrelate treatment improves polydipsia and polyuria, reduces platelet hyperactivation, plasma 5-HT and the vascular sympathetic tone, and changes 5-HT receptors inhibiting noradrenergic drive in diabetic rats: pre and/or postjunctional 5-HT1D/7 are involved in the sympatho-inhibition. [Display omitted] •Sarpogrelate decreases polyuria and polydipsia in type 1 diabetic rats.•Platelet activation is reduced in sarpogrelate-treated diabetic rats.•Sarpogrelate diminishes vascular sympathetic neurotransmission in diabetes.•The 5-HT vascular sympatho-inhibition is modified by sarpogrelate in diabetic rats.•Pre and/or postjunctional 5-HT1D and 5-HT7 are responsible of sympatho-inhibition.